CD54 (ICAM-1) Monoclonal Antibody (eBioKAT-1 (KAT-1, KAT1)), Functional Grade, eBioscience™, Invitrogen™

Description

Description: The eBioKAT-1 monoclonal antibody reacts with mouse CD54 (ICAM-1), which is a 95 kDa member of the immunoglobulin superfamily. CD54 is expressed at low levels on leukocytes and high endothelial venules, and expression increases in response to inflammatory cytokines. ICAM-1 binds to LFA-1 and this interaction is required for the transendothelial migration of T cells. ICAM-1-deficient mice are viable, however the migration of leukocytes to sites of inflammation is reduced leading to impaired immune and inflammatory responses. Based on the regulated expression of ICAM-1, it has been suggested that ICAM-1 may increase leukocyte extravasation at sites of inflammation, whereas the constitutively high expression of ICAM-2 mediates leukocyte traffic into non-inflamed tissue. The eBioKAT-1 monoclonal antibody recognizes a different epitope than the YN1/1.7.4 monoclonal antibody. Applications Reported: This eBioKAT-1 (KAT-1, KAT1) antibody has been reported for use in flow cytometric analysis, immunoprecipitation, and immunohistology staining of frozen tissue sections. The KAT-1 monoclonal antibody has also been reported to inhibit the in vivo ICAM-1-mediated migration of leukocytes. Applications Tested: This eBioKAT-1 (KAT-1, KAT1) antibody has been tested by flow cytometric analysis of mouse splenocytes. This can be used at less than or equal to 0.5 μg per test.

A test is defined as the amount (μg) of antibody that will stain a cell sample in a final volume of 100 μL. Cell number should be determined empirically but can range from 10^5 to 10^8 cells/test. It is recommended that the antibody be carefully titrated for optimal performance in the assay of interest. Endotoxin: Less than 0.001 ng/ug antibody as determined by the LAL assay. Storage and handling: Use in a sterile environment. Filtration: 0.2 μm post-manufacturing filtered. Purity: Greater than 90%, as determined by SDS-PAGE. Endotoxin Level: Less than 0.001 ng/μg antibody, as determined by LAL assay. Aggregation: Less than 10%, as determined by HPLC. ICAM-1 (CD54) is an 85-110 kDa single-chain type 1 integral membrane glycoprotein with an extracellular domain of five immunoglobulin superfamily repeats, a transmembrane region and a cytoplasmic domain. ICAM-1 has 7 potential N-linked glycosylation sites and shares considerable amino acid sequence homology with ICAM-3 (CD50) and ICAM-2 (CD102). ICAM-1 binds to integrins of type CD11a/CD18 (leukocyte adhesion molecule, LFA-1), or CD11b/CD18 (Mac-1) and is exploited by Rhinovirus as a receptor. ICAM-1 is expressed by activated endothelial cells and detected on epithelial cells, fibroblasts, chondrocytes, B lymphocytes, T lymphocytes (low), monocytes, macrophages, dendritic cells and neutrophils, with lower levels that increase upon inflammation. ICAM-1 is also detected in some carcinoma and melanoma cells. Soluble ICAM-1 is detectable in the plasma and is elevated in patients with various inflammatory syndromes.